Unveiling the contributions of immunization for progressing towards Universal Health Coverage

Hum Vaccin Immunother. 2022 Dec 31;18(1):2036048. doi: 10.1080/21645515.2022.2036048. Epub 2022 Mar 3.

Abstract

The aim of the United Nations' Sustainable Development Goal (SDG)3 is to ensure healthy lives and promote well-being for all, at all ages; including reducing maternal and child mortality, combating communicable and non-communicable diseases, and achieving Universal Health Coverage (UHC). UHC aims to provide everyone with equal access to quality essential and comprehensive healthcare services including preventions, interventions, and treatments, without exposing them to financial hardship. Making progress toward UHC requires significant investment in technical and financial resources and countries are pursuing the implementation of cost-saving measures within health systems to help them achieve UHC. Whilst many countries are far from attaining UHC, all countries, particularly low- and middle-income countries, can take steps toward achieving UHC. This paper discusses key data showing how immunization is a fundamental, cost-effective tool for reducing morbidity and mortality associated with infectious disease in all populations, creating more productive communities, reducing treatment costs, and consequently, facilitating social and economic advancement. Immunization is key to advancing toward UHC by relieving the burden that diseases place on the healthcare services, freeing essential resources to use elsewhere within the healthcare system. Immunization is an essential, readily available strategy that countries can deploy to achieve UHC and the SDG3 agenda.

Keywords: Universal Health Coverage; Vaccination; healthcare; immunization; public health.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Delivery of Health Care*
  • Health Care Costs
  • Humans
  • Immunization
  • Income
  • Universal Health Insurance*

Grants and funding

GlaxoSmithKline Biologicals SA funded the research and was involved in all stages of its conduct, including analysis and interpretation of the data. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and publication of this manuscript.